Background and objective: The association between angiotensin-converting enzyme (ACE) insertion/deletion (I/D) gene polymorphism and end-stage renal disease (ESRD) risk in IgA nephropathy (IgAN) patients is still controversial. A metaanalysis was performed to evaluate the association between ACE I/D gene polymorphism and ESRD susceptibility in IgAN patients. Method: A predefined literature search and selection of eligible relevant studies were performed to collect data from electronic databases. Results: Thirteen articles were identified for the analysis of the association between ACE I/D gene polymorphism and ESRD risk in IgAN patients. D allele and DD genotype were associated with ESRD susceptibility in IgAN patients for overall populations (p=0.01 and 0.003, respectively). In Asians, there was a markedly positive association between DD genotype and ESRD susceptibility (p=0.03). Furthermore, D allele and DD genotype were associated with ESRD susceptibility in Caucasians (p=0.02 and 0.03, respectively). However, II genotype might not play a protective role against ESRD onset for overall populations, Asians and Caucasians. Conclusion: DD homozygote is a significant genetic molecular marker for the onset of ESRD in IgAN patients.
Introduction
IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide, leading to end-stage renal disease (ESRD) in 20-30% of patients. 1 ESRD is an everincreasing problem worldwide and is a major health problem associated with very high morbidity and mortality. 2 Patients with ESRD display enhanced genomic damage, and DNA repair gene polymorphisms may affect DNA repair capacity and modulate susceptibility to ESRD. 3 Some investigations [4] [5] [6] [7] have suggested that genetic factors might play a key role in the onset of ESRD in IgAN patients.
Angiotensin-converting enzyme (ACE) inhibitors are important agents that can reduce the ACE level and slow down the progression of ESRD. The ACE gene consists of either an insertion (I) allele or a deletion (D) allele forming three possible genotypes: II, ID or DD. 8 The ACE I/D gene polymorphism, correlating with circulating and cellular ACE concentration, 9, 10 has been implicated in the etiology of ESRD in IgAN patients and has been investigated in numerous epidemiologic studies at present. However, the available evidence reported to date is weak because of sparseness of data or disagreements among studies. Meta-analysis exploring the association of ACE I/D gene polymorphism with ESRD risk in IgAN patients was rare. We performed this meta-analysis to investigate the relation between ACE I/D gene polymorphism and ESRD susceptibility in IgAN patients, with the intention to provide a much more reliable finding on the significance of the association.
Materials and methods

Search strategy
The relevant studies were screened from the search engines of PubMed, Embase, Cochrane Library and CBM-disc (China Biological Medicine Database) on 1 March 2012. "(End-stage renal disease OR ESRD OR kidney failure OR renal failure) AND (angiotensin converting enzyme OR ACE) AND gene" was used in PubMed, Cochrane Library and CBM-disc. The search in PubMed or in Embase was limited to humans and the English language. We also extended the search spectrum to the "related articles" and the bibliographies of all retrieved studies. If multiple publications from the same study group using the same data occurred, we recruited only the most complete paper for analysis.
Inclusion and exclusion criteria
Inclusion criteria: (1) case-control study; (2) the outcome had to be ESRD risk in IgAN patients; (3) there had to be at least two comparison groups (ESRD group vs control group).
Exclusion criteria: (1) review articles; (2) editorials/case reports; (2) same data for multiple publications; (3) investigating the association of other genes with ESRD in IgAN patients; (4) investigating the role of ACE level/ACE inhibitor with respect to ESRD in IgAN patients.
Data extraction and synthesis
The following information was extracted from each study independently by the investigators: first author's surname, year of publication, ethnicity of study population, and the number of cases and controls for ACE genotype. Frequencies of D allele were calculated for case group and control group from the corresponding genotype distribution. The results were compared and disagreements were resolved by discussion.
Statistical analysis
Available data were entered into Cochrane Review Manager (RevMan, version 5) and analyzed. The pooled statistic was counted using the fixed-effects model, but a random-effects model was conducted when the p value of heterogeneity test was less than 0.1. Results were expressed with odds ratios (OR) for dichotomous data, and 95% confidence intervals (CI) were also calculated. A p value of < 0.05 was required for the overall OR to be deemed statistically significant. I 2 was used to test the heterogeneity between the included studies. We classified the investigations into studies for Asians and Caucasians because genotype frequencies and prevalence of ESRD were different among ethnic groups. A Chi-square test using a web-based program was applied to determine if genotype distribution of the control population reported conformed to the Hardy-Weinberg equilibrium (HWE) (HWE; p < 0.05 was considered significant). Sensitivity analysis was performed when studies with controls were not in HWE. The Begg adjusted rank correlation test 11 and the Egger regression asymmetry test 12 were used for exploring publication bias (p < 0.1 was considered significant) when the number of the included studies was more than 10.
Results
Study characteristics
The search yielded 446 references, 267 from PubMed, 36 from Embase, 16 from Cochrane Library and 57 in CBMdisc. According to the inclusion and exclusion criteria, 13 articles were identified for the analysis of the association between ACE I/D gene polymorphism and ESRD susceptibility in IgAN patients in our review ( Figure 1 ). Eleven studies [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] were conducted in Asians, and two investigations 24, 25 were performed in Caucasians. Eleven articles were published in English [13] [14] [15] [16] [17] [18] [19] 21, [23] [24] [25] and two 20, 22 in Chinese. The data of our interest were extracted (Table 1 ). These 13 studies contained 609 case series and 1268 controls. The average frequency of the ACE D allele was 40.29% in Asian patients and 33.78% in controls. For Caucasians, the average frequency of D allele was 57.01% in the case group and 44.33% for controls. The ratio of cases/controls for average frequency of D allele in Caucasians was slightly higher compared with that in Asians (Caucasians: cases/controls = 1.29; Asians: cases/controls = 1.19).
Association of ACE I/D gene polymorphism with ESRD susceptibility in IgAN patients
There was a significant association between D allele/DD genotype and ESRD risk in all populations in this metaanalysis (D allele: p = 0.01, DD genotype: p = 0.003; see Figure 2 for D allele and Figure 3 for DD genotype; Table  2 ). In the sub-group study, the association of DD homozygote with ESRD risk was observed in Asians (p = 0.03). The D allele seemed to be associated with ESRD risk (D: OR = 1.24, 95% CI: 0.98-1.58), though the statistical difference was not found (p = 0.07; see Table 2 ). Furthermore, D allele and DD genotype were associated with the risk of ESRD in Caucasians (D: OR = 1.55, p = 0.02, DD: OR = 1.86, p=0.03).
In this meta-analysis, II seemed not to play a protective role against the ESRD risk for overall populations, Asians and Caucasians.
Sensitivity analysis
The genotype distributions of the control group in the recruited study were not in HWE, which was an important reason to cause heterogeneity. In this meta-analysis, sensitivity analysis was performed. The genotype distributions of the control population in four articles 17, 18, 20, 24 did not conform to HWE, and those investigations were excluded. Finally, nine studies were recruited into our sensitivity analysis: eight studies [13] [14] [15] [16] 19, [21] [22] [23] in Asians, and one 25 in Caucasians. We found that the results of the D allele and DD genotype for ESRD risk in overall populations were similar to those in the non-sensitivity analysis. In our sensitivity analysis, the D allele and DD homozygote were also associated with the onset of ESRD risk in Asians. However, the association of D allele or DD homozygote with ESRD susceptibility was not observed in Caucasians, and it was not consistent with that in the non-sensitivity analysis. II genotype seemed not to play a protective role against ESRD risk in overall populations, Asians and Caucasians, and the results were similar with those in the non-sensitivity analysis ( Table 2) .
Evaluation of publication bias
The publication bias for overall populations and Asians was evaluated. In the analysis for the association of ACE with ESRD in IgAN patients, no significant publication bias was shown for overall populations (Begg P=0.428, Egger P=0.138); and Asians (Begg P=0.876, Egger P=0.135). 
Discussion
In this investigation, 13 articles were recruited for metaanalysis: 11 studies in Asians, and two investigations in Caucasians. We found that the D allele and DD homozygote were associated with the onset of ESRD risk in overall populations, and the results from sensitivity analysis were similar with those in the non-sensitivity analysis, and there was no publication bias. The results of the D allele and DD homozygote for overall populations were robust. Furthermore, the DD genotype was associated with the onset of ESRD risk in Asians, and this result from sensitivity analysis was similar with that in the non-sensitivity analysis, and there was no publication bias. The result of DD genotype in Asians was robust. In the sensitivity analysis, D allele was associated with the risk of ESRD in Asians. Furthermore, the D allele seemed to be associated with the ESRD risk in the non-sensitivity analysis, though the statistical difference was not found. We might draw a conclusion that the D allele was also a risk genetic molecular marker for the onset of ESRD in Asians. To sum up, we may state that the D allele and DD homozygote were associated with the ESRD risk for overall populations and Asians. Interestingly, we found that the D allele and DD genotype were associated with the risk of ESRD in Caucasians. Unfortunately, we found that the D allele and DD genotype were not associated with the risk of ESRD in Caucasians in the sensitivity analysis. The results in the sensitivity analysis were not consistent with those from the non-sensitivity analysis. The number of the included studies for the meta-analysis in Caucasians was small (two for non-sensitivity analysis and one for sensitivity analysis), and it was difficult to draw a robust conclusion for Caucasians. More investigations on the Caucasian population should be performed in future to draw a robust result.
There are a number of publications indicating that II genotype may be a protective factor against renal diseases and the progression of renal diseases. [26] [27] [28] [29] [30] However, this association was not statistically significant in the present meta-analysis. In this study, we also observed that II homozygote was not associated with the onset of ESRD in overall populations, Asians and Caucasians. The results from the non-sensitivity analysis were consistent with those from the sensitivity analysis. In this meta-analysis, most of the included studies were from Asian populations. We found that the pooled OR for II genotype was favorable to the ESRD group in Asians or overall populations (Asians: OR = 0.89, p = 0.33; overall populations: OR = 0.85, p = 0.14), although the difference was not statistically significant. More studies investigating the role of II genotype for the ESRD risk in IgAN patients should be performed in the future.
Wiwanitkit 31 performed a meta-analysis including five studies and 346 cases and 555 controls. In his study, the frequency of DD genotype in the case group was significantly higher than in the control group. This conclusion was similar to ours. Our meta-analysis also performed a meta-analysis for D allele and performed a sensitivity analysis and tested the publication bias, but they weren't conducted in Wiwanitkit's study. 31 Furthermore, the number of included studies for meta-analysis in our study was much larger when compared with that of Wiwanitkit. 31 It might be safe to draw a conclusion that DD genotype is associated with ESRD risk.
In the past years, there were some meta-analyses to explore the association of ACE I/D gene polymorphism with the progression of diseases. Pereira et al. 32 performed a meta-analysis to investigate the association of ACE I/D gene polymorphism with ESRD risk in autosomal dominant polycystic kidney disease patients, and found that the DD genotype failed to show an influence on risk of ESRD. Yu et al. 27 conducted a meta-analysis in diabetic nephropathy patients that indicated that D allele or DD homozygous was associated with the ESRD susceptibility. The results in our study were similar to those results in patients with a diabetic nephropathy, but not for those with utosomal dominant polycystic kidney disease.
In the past decades, there were many studies reporting that angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) therapy might influence the progression to ESRD. 23, [33] [34] [35] Interestingly, Woo et al. 18 performed a study to investigate the effect of highdose ARB in IgAN patients, and found that patients treated with high-dose ARB, irrespective of the ACE gene polymorphism, whether it was DD, ID or II, would still respond with more effective reduction of proteinuria and retardation of progression to ESRD. The common mechanism of the ACEI is probably through lower level of ACE, glomerular pressure and proteinuria, resulting in reduced renal damage and retardation of progression to ESRD. 23 Furthermore, ARB, which interferes with the renin-angiotensin-aldosterone system and restricts the action of angiotensin II, has been shown to reduce proteinuria and slow down the progression of renal function deterioration. 36, 37 So, the increased ACE level might take part in the pathogenesis of ESRD.
In our investigation, we found that D allele or DD genotype was associated with ESRD susceptibility in overall populations and in Caucasians. Furthermore, DD genotype was associated with ESRD susceptibility in Asians. However, these findings should be regarded cautiously because many other ingredients, such as heterogeneity of enrolled cases, limited statistical power, variable study designs and different interventions, were closely related, affecting the results. Furthermore, whether the ACE I/D gene polymorphism is just linked with other discrete loci involved in the occurrence of ESRD is not clear at the moment.
Limitations
Some limitations should be discussed in this meta-analysis. First, heterogeneities might be present, affecting the results of our meta-analysis, although a random-effects model had been performed. Second, an important threat to any literature-based review and meta-analysis is that of reporting bias (recruiting published literature only in English and Chinese). Last but not least, the sample sizes in some studies were relatively small. Undoubtedly, the limitations mentioned above might affect our final conclusions.
Conclusions
The results in our study support D allele or DD genotype association with ESRD susceptibility in overall populations and in Caucasians. Furthermore, DD genotype is associated with ESRD susceptibility in Asians. DD homozygote might be a valuable indicator to predict the onset of ESRD in overall populations, Asians and Caucasians. However, more case-control association investigations on larger, stratified populations are required to further clarify the role of this ACE I/D gene polymorphism in ESRD susceptibility in IgAN patients of different ethnicities.
